Haixi Pharmaceuticals Launches Phase III Trial of First-in-Class C019199 Tablets for Refractory Osteosarcoma

Bulletin Express07-09

Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharmaceuticals) has formally commenced a multicenter, randomized, controlled, open-label Phase III clinical study (Protocol HXP019-CTPIII-02) to evaluate its proprietary C019199 tablets in patients with osteosarcoma who have failed at least two prior treatment lines.

The trial, registered under CTR20261818 with China’s Center for Drug Evaluation, plans to enroll approximately 120 participants nationwide. Progression-free survival assessed by a blinded independent review committee serves as the primary endpoint, while overall survival, objective response rate, disease control rate and safety constitute key secondary endpoints.

C019199 is described as a first-in-class, multi-target tumor immunomodulator derived from Haixi Pharmaceuticals’ MultiSel-Opt small-molecule R&D platform. Osteosarcoma, a malignant bone tumor prevalent among adolescents and young adults, has limited therapeutic options following relapse or metastasis, underscoring the clinical significance of the new trial.

The initiation of this Phase III study marks a pivotal milestone in Haixi Pharmaceuticals’ oncology pipeline, potentially advancing a novel therapeutic option for patients with advanced osteosarcoma. Investors and shareholders are advised to exercise caution when dealing in the company’s shares and to seek professional advice if in doubt.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1104564655?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-09 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1104564655","market":"us","top_or_hot":-1,"title":"Haixi Pharmaceuticals Launches Phase III Trial of First-in-Class C019199 Tablets for Refractory Osteosarcoma","media":"Bulletin Express","content":"<p>Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharmaceuticals) has formally commenced a multicenter, randomized, controlled, open-label Phase III clinical study (Protocol HXP019-CTPIII-02) to evaluate its proprietary C019199 tablets in patients with osteosarcoma who have failed at least two prior treatment lines.</p>\n<p>The trial, registered under CTR20261818 with China’s Center for Drug Evaluation, plans to enroll approximately 120 participants nationwide. Progression-free survival assessed by a blinded independent review committee serves as the primary endpoint, while overall survival, objective response rate, disease control rate and safety constitute key secondary endpoints.</p>\n<p>C019199 is described as a first-in-class, multi-target tumor immunomodulator derived from Haixi Pharmaceuticals’ MultiSel-Opt small-molecule R&D platform. Osteosarcoma, a malignant bone tumor prevalent among adolescents and young adults, has limited therapeutic options following relapse or metastasis, underscoring the clinical significance of the new trial.</p>\n<p>The initiation of this Phase III study marks a pivotal milestone in Haixi Pharmaceuticals’ oncology pipeline, potentially advancing a novel therapeutic option for patients with advanced osteosarcoma. Investors and shareholders are advised to exercise caution when dealing in the company’s shares and to seek professional advice if in doubt.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Haixi Pharmaceuticals Launches Phase III Trial of First-in-Class C019199 Tablets for Refractory Osteosarcoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHaixi Pharmaceuticals Launches Phase III Trial of First-in-Class C019199 Tablets for Refractory Osteosarcoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-09 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharmaceuticals) has formally commenced a multicenter, randomized, controlled, open-label Phase III clinical study (Protocol HXP019-CTPIII-02) to evaluate its proprietary C019199 tablets in patients with osteosarcoma who have failed at least two prior treatment lines.</p>\n<p>The trial, registered under CTR20261818 with China’s Center for Drug Evaluation, plans to enroll approximately 120 participants nationwide. Progression-free survival assessed by a blinded independent review committee serves as the primary endpoint, while overall survival, objective response rate, disease control rate and safety constitute key secondary endpoints.</p>\n<p>C019199 is described as a first-in-class, multi-target tumor immunomodulator derived from Haixi Pharmaceuticals’ MultiSel-Opt small-molecule R&D platform. Osteosarcoma, a malignant bone tumor prevalent among adolescents and young adults, has limited therapeutic options following relapse or metastasis, underscoring the clinical significance of the new trial.</p>\n<p>The initiation of this Phase III study marks a pivotal milestone in Haixi Pharmaceuticals’ oncology pipeline, potentially advancing a novel therapeutic option for patients with advanced osteosarcoma. Investors and shareholders are advised to exercise caution when dealing in the company’s shares and to seek professional advice if in doubt.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1104564655","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1104564655","pubTimestamp":1783586437,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharmaceuticals) has formally commenced a multicenter, randomized, controlled, open-label Phase III clinical study (Protocol HXP019-CTPIII-02) to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"海西药业启动First-in-Class C019199片治疗难治性骨肉瘤III期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"Fujian Haixi Pharmaceuticals Co., Ltd. (Haixi Pharmaceuticals) has formally commenced a multicenter, randomized, controlled, open-label Phase III clinical study (Protocol HXP019-CTPIII-02) to evaluate its proprietary C019199 tablets in patients with osteosarcoma who have failed at least two prior treatment lines.\nThe trial, registered under CTR20261818 with China’s Center for Drug Evaluation, plans to enroll approximately 120 participants nationwide. Progression-free survival assessed by a blinded independent review committee serves as the primary endpoint, while overall survival, objective response rate, disease control rate and safety constitute key secondary endpoints.\nC019199 is described as a first-in-class, multi-target tumor immunomodulator derived from Haixi Pharmaceuticals’ MultiSel-Opt small-molecule R&D platform. Osteosarcoma, a malignant bone tumor prevalent among adolescents and young adults, has limited therapeutic options following relapse or metastasis, underscoring the clinical significance of the new trial.\nThe initiation of this Phase III study marks a pivotal milestone in Haixi Pharmaceuticals’ oncology pipeline, potentially advancing a novel therapeutic option for patients with advanced osteosarcoma. Investors and shareholders are advised to exercise caution when dealing in the company’s shares and to seek professional advice if in doubt.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1104564655","isCrawlerRequest":true}